Evidence map›Paper›PMID 23285210›Full record

ArticlePloS one2012

Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR₃₄/L98H mutations in the cyp51A gene in India.

Anuradha Chowdhary, Shallu Kathuria, Jianping Xu, Cheshta Sharma, Gandhi Sundar, Pradeep Kumar Singh, Shailendra N Gaur, Ferry Hagen, Corné H Klaassen, Jacques F Meis

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 192 citations in OpenAlex.

  1. Trial
  2. Review
  3. Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026
    Review
  4. Article
  5. Article
  6. Pathogenic Aspergillus spp. and Candida spp. in coastal waters from southern Brazil: an one health approach.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Assessing thermal adaptation of a global sample ofFrontiers in public health · 2023
    Article
  15. Article
  16. Article
  17. Clinical utility of antifungal susceptibility testing.JAC-antimicrobial resistance · 2022
    Review
  18. Article
  19. Article
  20. Phylogenetic Distribution ofMicrobiology spectrum · 2021
    Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Anuradha ChowdharyDepartment of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India. dranuradha@hotmail.com
Shallu Kathuria
Jianping Xu
Cheshta Sharma
Gandhi Sundar
Pradeep Kumar Singh
Shailendra N Gaur
Ferry Hagen
Corné H Klaassen
Jacques F Meis
University of Delhi · INCanisius-Wilhelmina Ziekenhuis · NLMcMaster University · CARadboud University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azole resistance is an emerging problem in Aspergillus which impacts the management of aspergillosis. Here in we report the emergence and clonal spread of resistance to triazoles in environmental Aspergillus fumigatus isolates in India. A total of 44 (7%) A. fumigatus isolates from 24 environmental samples were found to be triazole resistant. The isolation rate of resistant A. fumigatus was highest (33%) from soil of tea gardens followed by soil from flower pots of the hospital garden (20%), soil beneath cotton trees (20%), rice paddy fields (12.3%), air samples of hospital wards (7.6%) and from soil admixed with bird droppings (3.8%). These strains showed cross-resistance to voriconazole, posaconazole, itraconazole and to six triazole fungicides used extensively in agriculture. Our analyses identified that all triazole-resistant strains from India shared the same TR(34)/L98H mutation in the cyp51 gene. In contrast to the genetic uniformity of azole-resistant strains the azole-susceptible isolates from patients and environments in India were genetically very diverse. All nine loci were highly polymorphic in populations of azole-susceptible isolates from both clinical and environmental samples. Furthermore, all Indian environmental and clinical azole resistant isolates shared the same multilocus microsatellite genotype not found in any other analyzed samples, either from within India or from the Netherlands, France, Germany or China. Our population genetic analyses suggest that the Indian azole-resistant A. fumigatus genotype was likely an extremely adaptive recombinant progeny derived from a cross between an azole-resistant strain migrated from outside of India and a native azole-susceptible strain from within India, followed by mutation and then rapid dispersal through many parts of India. Our results are consistent with the hypothesis that exposure of A. fumigatus to azole fungicides in the environment causes cross-resistance to medical triazoles. The study emphasises the need of continued surveillance of resistance in environmental and clinical A. fumigatus strains.

Indexed as

Amino Acid SubstitutionAntifungal AgentsAspergillus fumigatusClone CellsColony Count, MicrobialCytochrome P-450 Enzyme SystemDrug Resistance, Multiple, FungalEnvironmentFungal ProteinsFungicides, IndustrialHistidineHumansIndiaLeucineMutation, MissenseTandem Repeat SequencesAntifungal Agentscytochrome P-450 CYP51A, AspergillusCytochrome P-450 Enzyme SystemFungal ProteinsFungicides, IndustrialHistidineLeucineTriazoles

Identifiers

PMID23285210
PMCPMC3532406
OpenAlexW2073488008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.